877071-33-5

Basic information

• Product Name: Imidazo[1,2-a]pyridine, 6-bromo-2-[[(4-methylphenyl)sulfonyl]methyl]-3-nitro-
• CAS NO: 877071-33-5
• Molecular Formula: C15H12BrN3O4S
• Molecular Weight: 410.248
• Mol File: 877071-33-5.mol

Chemical Properties

• CAS DataBase Reference: Imidazo[1,2-a]pyridine, 6-bromo-2-[[(4-methylphenyl)sulfonyl]methyl]-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridine, 6-bromo-2-[[(4-methylphenyl)sulfonyl]methyl]-3-nitro-(877071-33-5)
• EPA Substance Registry System: Imidazo[1,2-a]pyridine, 6-bromo-2-[[(4-methylphenyl)sulfonyl]methyl]-3-nitro-(877071-33-5)

Safety Data

• Hazardous Substances Data: 877071-33-5(Hazardous Substances Data)

Upstream product

• 136117-72-1 6-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine 
• 98-59-9 p-toluenesulfonyl chloride 
• 1072-97-5 5-bromo-2-pyridylamine 
• 824-79-3 sodium 4-methylbenzenesulfinate 

Relevant articles and documents

An efficient synthetic route to new imidazo[1,2-a]-pyridines by cross-coupling reactions in aqueous medium

The Suzuki cross-coupling reaction of 6-bromo-3-nitro-2-phenylsulfonylmethylimidazo[1,2-a]pyridine and 6-bromo-3-nitro-2-tosylmethylimidazo[1,2-a]pyridine provided an efficient route to the corresponding 6-aryl-3-nitro-2-phenylsulfonylmethylimidazo[1,2-a]

Targeting the human parasite Leishmania donovani: Discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series

We report herein the discovery of antileishmanial molecules based on the imidazo[1,2-a]pyridine ring. In vitro screenings of imidazopyridines belonging to our chemical library, toward the promastigotes stage of Leishmania donovani, J774A.1 murine and HepG2 human cells, permitted to identify three selective hit-compounds (12, 20 and 28). New derivatives were then synthesized to allow structure-activity and -toxicity relationships analyses, enabling to characterize a lead-compound (44) displaying both a high potency (IC 50 = 1.8 μM) and a good selectivity index, in comparison with three antileishmanial reference drug-compounds (amphotericin B, miltefosine and pentamidine). Moreover, lead-compound 44 also exhibits good in vitro activity against the intracellular amastigote stage of L. donovani. Thus, the 6-halo-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine scaffold appears as a new promising selective antileishmanial pharmacophore, especially when substituted at position 8 by a bromine atom.

Synthesis and structural characterization of three phenylsulfonyl derivatives: Influence of halogen substituents on the intermolecular interactions

Synthesis and X-ray structural determination of three halogenated nitroimidazo[1,2-a]pyridine phenylsulfonyl derivatives are reported. (2) is monoclinic P21/c with a = 9.6679(1), b = 11.3642(2), c = 15.2189(2)A, β = 105.9053(7)°; (3) is triclin